Johnson & Johnson (JNJ) Assets Average (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Assets Average came in at $200.1 billion in Q1 2026, up 7.04% year-on-year from $186.9 billion in Q1 2025, and up 2.06% quarter-over-quarter from $196.0 billion in Q4 2025.
Johnson & Johnson (JNJ) Assets Average (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Assets Average across 18 years of filings, most recently posting $200.1 billion for Q1 2026.
- Assets Average for Q1 2026 came in at $200.1 billion, up 7.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $200.1 billion (up 7.04% YoY), and the FY2025 annual result was $189.7 billion, up 9.1% from the prior year.
- Assets Average came in at $200.1 billion for Q1 2026 at Johnson & Johnson, up from $196.0 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $200.1 billion in Q1 2026 to a low of $166.8 billion in Q4 2023.
- The 5-year median for Assets Average is $180.4 billion (2022), against an average of $183.5 billion.
- Across the five-year window, Assets Average declined 11.43% in 2024 and gained 10.09% in 2025, its largest moves.
- Johnson & Johnson's Assets Average stood at $176.4 billion in 2022, then fell by 5.45% to $166.8 billion in 2023, then grew by 7.43% to $179.2 billion in 2024, then rose by 9.39% to $196.0 billion in 2025, then rose by 2.06% to $200.1 billion in 2026.
- The last three Assets Average figures came in at $200.1 billion (Q1 2026), $196.0 billion (Q4 2025), and $193.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 83.03 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 114.53 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 200.05 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 135.21 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 132.78 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 91.55 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 57.65 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 208.08 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 88.26 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 200.05 Bn |
| Dec 28, 2025 | 196.01 Bn |
| Sep 28, 2025 | 193.10 Bn |
| Jun 29, 2025 | 193.53 Bn |
| Mar 30, 2025 | 186.89 Bn |
| Dec 29, 2024 | 179.20 Bn |
| Sep 29, 2024 | 179.69 Bn |
| Jun 30, 2024 | 176.53 Bn |
| Mar 31, 2024 | 169.76 Bn |
| Dec 31, 2023 | 166.81 Bn |
| Oct 1, 2023 | 178.87 Bn |
| Jul 2, 2023 | 193.83 Bn |
| Apr 2, 2023 | 191.67 Bn |
| Jan 1, 2023 | 181.25 Bn |
| Oct 2, 2022 | 176.42 Bn |
| Jul 3, 2022 | 178.04 Bn |
| Apr 3, 2022 | 180.19 Bn |
| Jan 2, 2022 | 180.62 Bn |
| Oct 3, 2021 | 177.83 Bn |
| Jul 4, 2021 | 174.50 Bn |